Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 1998

View Archived Issues

Company Profile: Medarex

Progenics, Roche collaborate on next-generation anti-HIV agents

Interim results reported for ziconotide phase III pain study

Pivotal trial of PROSORBA column in RA stopped early due to favorable results

Japanese marketing agreement announced for Bio-Technology General's hGH

Texas Biotechnology prepares new endothelin modulators

New class of glucocorticoids with an improved pharmacological profile

Pharma Mar discovers new antitumor heptapeptide from Australian ascidian

Overview of antiviral agents in hepatic disease

Prodrugs of COX-2 inhibitors prepared at Searle

Lilly describes new glycopeptides active against VRE

Phthalazine AMPA receptor antagonists claimed by Schering AG

Modulators of muscarinic receptors claimed by Lilly for AD, psychosis

New proto-oncogene inhibitor isolated from fungus by Schering-Plough

Kyowa Hakko characterizes new MLCK inhibitors from soil fungus

FDA approves first OTC drug for migraine

Schering-Plough discovers dual NK1/NK2 antagonists from fungal strain

Idun licenses novel protein technology from Thomas Jefferson University

TGF-beta mimic discovered in fungal culture by Japanese scientists

PD diagnostic technology available for licensing from NIH

Pacific receives patent allowance for immune system stimulant

Dysentery vaccine technology available for licensing from NIH

CoCensys spins off new company focused on apoptosis screening technology

HIV RT inhibitors available for licensing from NIH

Genzyme General discontinues U.S. development of Sepracoat

New PAF antagonists disclosed by Korean investigators

Three new AIDS vaccine trials examine novel approaches

Novel tumor vaccine technology described by U.S. researchers

FDA clears new indication for Rythmol

Phase III trials of Natrecor BNP now successfully completed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 11, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...